Fig. 5From: Pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort studyThe changes of safety parameters. The trajectory of score on HAMD and PSQI a and the occurrence of adverse events b were displayed in detailsBack to article page
